Simplify Prior Authorization
A Rheumatologist's Perspective on Prior Authorization and Timely Access to Treatments
In this episode of the Simplify Prior Authorization podcast series Denise Balch once again speaks to Dr. Imtiaz Khan, a licensed rheumatologist in Canada and the U.S. Dr. Khan is the former Head of Rheumatology at The Mississauga Hospital and is now in private practice and continues to be active in clinical research. Dr. Khan became Chair of the Ontario Rheumatologists Association (ORA) Private Payers committee in 2019.
Dr. Khan shares his insights into how new developments in the treatment of rheumatoid arthritis are changing patient treatment, including the introduction of biosimilars and new small molecules taken orally known as Janus kinase (JAK) inhibitors. He speaks to the efficiencies the electronic specialty authorization claims process for public payers in Ontario (SADIE) has created, and opportunities for the private sector to benefit from electronic prior authorization to ease the administrative burden and patient wait times without compromising drug cost management.
In this episode of the Simplify Prior Authorization podcast series Denise Balch once again speaks to Dr. Imtiaz Khan, a licensed rheumatologist in Canada and the U.S. Dr. Khan is the former Head of Rheumatology at The Mississauga Hospital and is now in private practice and continues to be active in clinical research. Dr. Khan became Chair of the Ontario Rheumatologists Association (ORA) Private Payers committee in 2019.
Dr. Khan shares his insights into how new developments in the treatment of rheumatoid arthritis are changing patient treatment, including the introduction of biosimilars and new small molecules taken orally known as Janus kinase (JAK) inhibitors. He speaks to the efficiencies the electronic specialty authorization claims process for public payers in Ontario (SADIE) has created, and opportunities for the private sector to benefit from electronic prior authorization to ease the administrative burden and patient wait times without compromising drug cost management.